High salt intake is a risk for developing resistant hypertension, and even under triple therapy with diuretics, an angiotensinconverting enzyme inhibitor/angiotensin receptor blocker and a calcium channel blocker, the volume is occasionally not controlled. In such cases, a mineralocorticoid receptor (MR) antagonist additively lowers the circulating blood volume and blood pressure despite the lower circulating aldosterone level. This mechanism may be explained by the increase in the number of MR under some conditions or the activation of these receptors independent of aldosterone. Future diagnostic tools to evaluate receptor activity may be valuable for the proper diagnosis and choice of therapy. Additionally, basic research has suggested that oxidative stress and the renin-angiotensin-aldosterone system in the brain represent new targets for the treatment of resistant hypertension.
INTRODUCTION
Resistant hypertension is defined as uncontrolled blood pressure (BP) under treatment with at least three drugs, including diuretics, and with all agents prescribed at optimal doses. 1 A survey showed that 20-30% of hypertensive patients require three or more antihypertensive agents and that resistant hypertensives are at high risk for target organ damage. [2] [3] [4] [5] [6] [7] Several factors associated with poor BP control include older age, severe hypertension, chronic kidney disease, female sex, obesity and diabetes mellitus, but the mechanism underlying resistant hypertension remains poorly understood. Several clinical studies have shown that the expansion of the circulating volume, greater cardiac output and/or vascular resistance are pathophysiological features of resistant hypertension and that the most common etiology is excessive salt intake. 8 Even though these patients are treated with diuretics, how does salt intake overcome the effect of diuretics? Why is salt restriction effective in resistant hypertensives? One possible explanation is that diuretics, with thiazide being the most commonly used, are not fully effective at the clinically used dosage. Older and recent clinical and basic research studies have suggested how excessive salt intake under thiazide treatment leads to resistant hypertension.
THIAZIDE AND VOLUME CONTROL Thiazide blocks the sodium-chloride channel (NCC) at the distal nephron, thereby inhibiting sodium resorption and reducing the circulating volume. A previous clinical study revealed that 50 mg of hydrochlorothiazide can reduce the circulating volume for only few days after its administration, with the circulating volume almost returning to the baseline, the extracellular volume remaining suppressed and the BP being maintained lower than the baseline. 9 These results suggested that thiazide treatment cannot replace dietary sodium restriction therapy, which decreases both the circulating and extracellular volume. Moreover, in cases of resistant hypertension with advanced chronic kidney disease, the glomerular filtration rate (o30 ml min À1 ) and medullary blood flow are impaired, and thiazide cannot block the NCC fully because it cannot be delivered effectively to the proximal tubule, where thiazide dissociates from its binding protein and is excreted to the tubules to reach the NCC at the distal tubule.
In addition to these issues regarding thiazide, when considering the sodium metabolism in the kidney from the proximal tubules to the collecting ducts, there are several sodium exchangers, and 60% of sodium is reabsorbed in the proximal tubules but o20% is reabsorbed in the distal nephron. Therefore, even after the complete inhibition of the NCC, dietary salt can be reuptaken up by other channels. To control blood volume, loop diuretics and aldosterone blockers are required. Indeed, clinical studies have shown that the addition of an aldosterone antagonist additively lowers BP in resistant hypertensives. 5, 10, 11 ALDOSTERONE AND SALT-RELATED RESISTANT HYPERTENSION Classically, the role of aldosterone in hypertension is to activate the epithelial sodium channel (ENaC) in the distal nephron to promote sodium reuptake. Recently, the aldosterone receptor in the blood vessel was reported to also have an important role in the development of hypertension (Figure 1 ). 12 A study in blood vessel-specific mineralocorticoid receptor (MR)-deficient mice revealed that MR can increase the expression of voltage-gated calcium channels, which raises the peripheral resistance. However, renal MR activity, as evaluated by the transtubular potassium gradient (TTKG), could not indicate the effectiveness of the add-on therapy of an MR antagonist in hypertensives. 13 Under high salt intake, the systemic renin-angiotensin-aldosterone axis is suppressed. In most cases of resistant hypertension, renin-angiotensin inhibitors (angiotensinconverting enzyme (ACE) inhibitors, angiotensin II receptor antagonists or renin inhibitors) are used, and plasma aldosterone levels are not high. Even under these conditions, aldosterone receptor blockade is effective in lowering BP.
The effectiveness of MR antagonists irrespective of the circulating aldosterone levels can be explained by several mechanisms: (1) the number of MRs increases, (2) MR is activated independently of aldosterone and (3) indirect effects of the MR antagonist partly due to sympatho-excitation, oxidative stress and other factors. Under high oxidative stress conditions, such as diabetes or ischemia, the number of MRs increases in the kidney or brain, as shown in studies with rodent models. 14, 15 In humans, the degree of proteinuria parallels MR expression and MR signaling in the kidney. 16 Both high oxidative stress and impaired renal function are common characteristics of resistant hypertension, and these mechanisms may explain the effectiveness of an MR antagonist as an adjuvant to conventional therapy. In addition to the regulation of MR expression, a recent study showed that MR can be activated in the kidney by rac1, a small G-protein, and that constitutively active rac1 causes saltsensitive hypertension. 17, 18 The factors that activate rac1 in the kidney either in hypertension or by dietary salt intake are still unknown. One possible pathway is that local angiotensin II activates Src-kinase, which in turn activates T-cell lymphoma invasion and metastasis 1 (Tiam1); Tiam1 is known to activate several nuclear transcription factors through rac1 induction. 19 The rac1-MR pathway might have a role in MR activation in resistant hypertension (Figure 1) .
Another study revealed that cyclin-dependent kinase 5 (CDK 5) phosphorylates MR to activate and subsequently increase the transcription of brain-derived neurotrophic factor in the brain. Whether the CDK 5-mediated MR activation in the brain regulates the transcription of other genes closely related to BP control remains unknown, but there are substantial data that MR activation has a pivotal role in controlling BP in the brain.
Aldosterone-mediated MR activation in the brain increases the ouabain-like substance 20 and the transcription of angiotensinogen, ACE and angiotensin II receptor type 1 (AT1). 21, 22 It also increases oxidative stress or sensitizes the effect of angiotensin II, thereby activating the paraventricular nucleus to induce sympathoactivation. 21, 22 In addition to these factors, MR has been reported to activate sympathetic tone via genomic action at either the rostral ventrolateral medulla (RVLM) 23 or choroid plexus 24 in stroke-prone SHR. Serum-and glucocorticoid-induced protein kinase-1 (sgk1) transcription is monitored at the RVLM as a marker of MR activation, although whether SgK1 directly activates the sympathetic tone has not been demonstrated.
In the choroid plexus, the MR activates ENaC as in the kidney to increase sodium in the spinal fluid. A small rise of the sodium level in the spinal fluid augments RVLM activity and BP by increasing oxidative stress and activating the MR. 23, 25 Moreover, in the hippocampus under physiological conditions, the non-genomic action of the MR is evoked by glucocorticoid. 26 Taken together, in RVLM, not only aldosterone but also CDK 5, rac1 or glucocorticoid may activate the MR to enhance the sympathetic tone and result in the development of sustained hypertension (Figure 1) .
One additional effect of an MR blockade in resistant hypertension and salt-induced hypertension is the blocking of oxidative stress. As mentioned above, oxidative stress can enhance MR expression and action, and the blockade of MR suppresses the production of oxidative stress via the inhibition of NADPH oxidase or via a calcium-dependent manner in various organs. [27] [28] [29] [30] In resistant hypertension, diuretics are often used, and a clinical study suggested that an MR antagonist would prevent diureticinduced sympathetic tone. 31 The precise mechanism with respect to whether the sympatholytic effect occurs via the central MR or renal MR remains unknown, but this additive effect may also explain the effects of an MR antagonist in resistant hypertensives who are treated with thiazide diuretics.
ANGIOTENSIN II AND SODIUM HOMEOSTASIS
Angiotensin II receptor type 1 and type 2 (AT1 and AT2, respectively) regulate sodium excretion. The AT1 receptor regulates sodium excretion in the proximal tubule and distal tubule. Cross-transplantation of the kidney suggested that the AT1 receptor in the kidney has the dominant role in the BP response to angiotensin II, 32 and when angiotensinogen and renin are overexpressed in the proximal tubules, hypertension develops. 33 Moreover, proximal tubule-specific AT1-deficient mice had lower BP but a similar BP response to salt compared with wild-type mice. In wild-type mice, angiotensin II elevates BP and decreases the level of sodium-hydrogen exchanger (NHE) 3, whereas in proximal tubule AT1-deficient mice, Figure 1 The cross-talk between salt and the renin-angiotensin-aldosterone system in resistant hypertension. Under high salt intake, the reninangiotensin-aldosterone system (RAAS) is suppressed, and oxidative stress (ROS) increases. In the brain, the increased ROS activates the sympathetic tone and local RAAS. The local RAAS increases the ROS in the brain, followed by interactions among angiotensin II (AII), aldosterone (Ald)/ mineralocorticoid receptor (MR) and the ROS. Efferent sympathetic tone activates the RAAS in the kidney to promote sodium resorption in the kidney and vascular tone in the vascular smooth muscle cells (VSMC). In the kidney, in addition to the local RAAS, the MR is activated by rac1 to further increase sodium resorption. An unknown sensory system may transmit signals to the brain to further increase the sympathetic output. In VSMC, angiotensin II receptor type 1 (AT1) and MR increase contractility by enhancing the calcium influx.
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T Shimosawa NHE3 is further decreased, resulting in a negative sodium balance. These data suggest that angiotensin II blocks the suppression of NHE3 by high BP via AT1 and that therefore pressure-natriuresis is impaired. 34 The precise mechanism by which NHE3 transcription is regulated by pressure and angiotensin II requires further investigation.
In addition to the effect on the proximal tubules, angiotensin II activates ENaC in both an acute and chronic fashion. Acute ENaC activation partly occurs via oxidative stress. 35 In contrast, the AT2 receptor promotes sodium excretion directly or indirectly by acting on the kidney. 36, 37 A pharmacological study involving the interstitial administration of angiotensin II, III and AT2 receptor blockers revealed that angiotensin II and III induce natriuresis via the AT2 receptor. 36 The AT1 and AT2 receptors have also been identified in the brain, and the microinjection of angiotensin II into the nucleus in the brain elicits an increase in BP and sympathetic activation via the AT1 receptor. In contrast, AT2 receptor activation induces a potassium channel current by increasing the probability of open channels 38 in vivo experiments showed that overexpression of the AT2 receptor at RVLM suppressed the sympathetic tone and induced a diuretic effect. 37 Whether angiotensin III is a ligand for the AT2 receptor in the brain is unknown, but AT2 receptor activation counteracts the AT1 receptor in the control of the circulating volume. ACE inhibitors block angiotensin II production, and therefore, the activation of both AT1 and AT2 is reduced, which, overall, maintains the sodium balance at a neutral level. An AT1 blocker can block sodium resorption in both the proximal and distal nephron directly and via a sympatholytic effect, and together with thiazide, it could result in a negative sodium balance.
Therapeutic doses of an ACE inhibitor, AT1 receptor blocker or renin inhibitor may not be high enough to inhibit either the circulating or locally produced angiotensin II (AII) effect, but AT1/2 receptor signaling may also be regulated independently of AII. [39] [40] [41] [42] [43] [44] The factors in resistant hypertension that can alter AT1/2 receptor activation, such as the bradykinin receptor, eceptor-associated proteins or other proteins, require future research.
PERSPECTIVES
It is well accepted that an MR blockade should be considered as a pharmacological intervention in resistant hypertensives partly because B20% of resistant hypertension comprises undiagnosed primary aldosteronism. 45 In addition to the failure of a proper diagnosis, recent studies have suggested that circulating aldosterone is not necessarily a marker of MR activation and that even at low aldosterone levels, MR antagonists are effective in lowering BP and protecting target organs. Not only MR but also the AT1 and AT2 receptors could be activated despite the suppression of circulating renin or AII. New diagnostic tools to evaluate the renin-angiotensinaldosterone axis status with respect to their receptor activities, such as the AT1/2 receptors and MR, in the kidney, brain or vasculature in resistant hypertensives may open a new pathway to understand the pathophysiology of resistant hypertension and enable therapies to be tailor-made.
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